Illumina has recently unveiled a groundbreaking spatial transcriptomics technology, slated for commercial release in 2026. This innovative solution is designed to empower researchers to map complex tissues and understand cellular behavior at an unprecedented scale. By providing researchers with advanced tools to study complex tissue structures and cellular interactions, the innovation has the potential to transform understanding of various diseases and accelerate the development of targeted therapies, says GlobalData, a leading data and analytics company.
Graysen Vigneux, Medical Analyst at GlobalData, comments: “The introduction of Illumina’s spatial transcriptomics technology marks a significant milestone in the field of genomics. By delivering unbiased whole-transcriptome profiling with cellular resolution and high sensitivity, Illumina’s spatial technology is poised to drive the expansion of spatial research and unlock applications previously deemed unfeasible.”
Spatial transcriptomics enables scientists to explore biological interactions at the cellular level. Through “cell atlasing,” which maps the detailed arrangement of cells, researchers can gain novel insights into complex tissue structures that influence disease. This advancement facilitates discoveries in areas such as tumor microenvironments, disease pathways, neurobiology, and immuno-oncology.
Illumina’s spatial technology allows for the examination of the spatial proximity of millions of cells per experiment, featuring a capture area nine times larger than existing technologies and four times greater resolution. This capability enables the identification of rare cell populations and enhances statistical power, providing greater confidence in research findings. Compatible with Illumina’s NextSeq and NovaSeq sequencers, this solution offers a more affordable price point for single-cell and spatial researchers, thereby reducing the cost of large-scale programs.
To complement this technological advancement, Illumina is introducing a new software platform, Illumina Connected Multiomics (ICM). ICM is a multimodal analysis platform that simplifies the visualization of spatial experiment results. It enables researchers to navigate, explore, and analyze multiomic datasets, ultimately driving deeper insights from biological data. The intuitive design and integration with the sequencing workflow allow scientists to generate powerful statistical insights and interactive visualizations, decoding multiple complex modalities such as genomic, proteomic, spatial transcriptomic, epigenetic, and single-cell data within a single platform.
Vigneux conclusion: “Spatial transcriptomics introduces an opportunity to explore cellular function with unprecedented detail. Illumina’s spatial technology enhances its sequencing platforms by providing a comprehensive workflow tailored for high-resolution spatial analysis. This innovation sets a new benchmark in scientific research, paving the way for transformative discoveries and a deeper understanding of biology.”
